Our top pick for
Soliton, Inc is a medical devices business based in the US. Soliton shares (SOLY) are listed on the NASDAQ and all prices are listed in US Dollars. Soliton employs 9 staff and has a market cap (total outstanding shares value) of USD$167.2 million.
Since the stock market crash in March caused by coronavirus, Soliton's share price has had significant negative movement.
Its last market close was USD$7.32, which is 42.68% down on its pre-crash value of USD$12.77 and 10.24% up on the lowest point reached during the March crash when the shares fell as low as USD$6.64.
If you had bought USD$1,000 worth of Soliton shares at the start of February 2020, those shares would have been worth USD$601.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$600.02.
|Latest market close||USD$7.32|
|52-week range||USD$5.69 - USD$15.5|
|50-day moving average||USD$7.9917|
|200-day moving average||USD$8.3713|
|Wall St. target price||USD$16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.874|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-15)||N/A|
|1 month (2020-10-26)||-10.29%|
|3 months (2020-08-22)||N/A|
|6 months (2020-05-22)||N/A|
|1 year (2019-11-22)||N/A|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-35.69%|
|Return on equity TTM||-63.66%|
|Market capitalisation||USD$167.2 million|
TTM: trailing 12 months
There are currently 1.9 million Soliton shares held short by investors – that's known as Soliton's "short interest". This figure is 2.9% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Soliton shares can be evaluated.
Soliton's "short interest ratio" (SIR) is the quantity of Soliton shares currently shorted divided by the average quantity of Soliton shares traded daily (recently around 220393.26364692). Soliton's SIR currently stands at 8.61. In other words for every 100,000 Soliton shares traded daily on the market, roughly 8610 shares are currently held short.
However Soliton's short interest can also be evaluated against the total number of Soliton shares, or, against the total number of tradable Soliton shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Soliton's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Soliton shares in existence, roughly 90 shares are currently held short) or 0.1944% of the tradable shares (for every 100,000 tradable Soliton shares, roughly 194 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Soliton.
Find out more about how you can short Soliton stock.
We're not expecting Soliton to pay a dividend over the next 12 months.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers product for the removal of tattoos. It also develops product for cellulite reduction, fibrotic scar treatment, and other indications. The company was founded in 2012 and is based in Houston, Texas.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.